Shanghai Fosun Pharmaceutical (Group) (HKG:2196) said China's National Medical Products Administration (NMPA) approved Botulinum Toxin Type A for Injection new drug application, according to a Wednesday filing with the Hong Kong bourse.
The drug, which is used for treating cervical dystonia in adults, was licensed to the company's unit, Fosun Pharmaceutical Industrial.